[Jaundice and portal cavernoma].
Condat
Bertrand
B
Service d'Hépatogastroentérologie, Hôpital Saint Camille, Bry-sur-Marne. B.Condat@ch-bry.org
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001651:Cholestasis, Extrahepatic / Q000209:etiology; D015331:Cohort Studies; D003937:Diagnosis, Differential; D005500:Follow-Up Studies; D006392:Hemangioma, Cavernous / Q000150:complications / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007565:Jaundice / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D011169:Portal Vein; D011433:Propranolol / Q000627:therapeutic use; D011860:Radiography, Abdominal; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D019043:Vascular Neoplasms / Q000150:complications / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy; D014665:Vasodilator Agents / Q000627:therapeutic use; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D014665:Vasodilator Agents; D014812:Vitamin K; D011433:Propranolol; D006918:Hydroxyurea